Australian Coat of Arms

PB 10 of 2026

National Health (April 2026 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2026  

National Health Act 1953

I, Rebecca Richardson, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.

Dated 26 February 2026

 

 

 

 

 

 

 

 

REBECCA RICHARDSON

Assistant Secretary

PBS Listing, Pricing and Policy Branch

Technology Assessment and Access Division

Department of Health, Disability and Ageing

 

1    Name  

(1)   This instrument is the National Health (April 2026 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2026.

(2)   This instrument may also be cited as PB 10 of 2026.

2             Commencement

   This instrument commences on 1 April 2026.

3             Authority

 

This instrument is made under subsection 99ACF(3) of the National Health Act 1953.

4            Definition

      Note: A number of expressions used in this instrument are defined in Part VII the Act.

 

In this instrument:

  

 Act means the National Health Act 1953.

 

Reduction day in this instrument refers to 1 April 2026.

5 Brand of pharmaceutical item not subject to a price reduction

 

  I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is not reduced under a provision mentioned in item 2A or item 3A or item 4A of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day.

6 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply

 

    I determine, under paragraph 99ACF(3)(b) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of a brand of pharmaceutical item specified in column 2 of an item in the table in Schedule 2 is reduced under a provision mentioned in item 4A of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day by the percentage specified in column 3 of the table item. 

Schedule 1 Brands of pharmaceutical items with approved ex-manufacturer price not reduced

 

Column 1

Column 2

Item

Brand of Pharmaceutical Item

 

Drug

Form

Manner of administration

Brand(s)

1

Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides

Oral powder 400 g (Essential Care Jr)

 

Oral

Essential Care Jr

 

2

Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides

Oral powder 400 g (Neocate Junior)

Oral

Neocate Junior

3

Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides

Oral powder 400 g (Neocate Gold)

Oral

Neocate Gold

 

4

Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides

Oral powder with 2'-fucosyllactose and lacto-N-neotetraose, 400 g (Alfamino)

Oral

Alfamino

5

Azacitidine

Tablet 200 mg

Oral

Onureg

6

Azacitidine

Tablet 300 mg

Oral

Onureg

7

Cetrorelix

Powder for injection 250 micrograms (as acetate) with diluent

Injection

Cetrotide

8

Citrulline with carbohydrate

Sachets of oral powder 4 g containing 1 g citrulline, 30 (Citrulline 1000)

Oral

Citrulline 1000

9

Degarelix

Powder for injection 80 mg (as acetate), injection set

Injection

Firmagon 80 mg

10

Degarelix

Powder for injection 120 mg (as acetate), 2, injection set

Injection

Firmagon 120 mg

11

Dupilumab

Injection 200 mg in 1.14 mL single dose pre-filled syringe

Injection

Dupixent

12

Dupilumab

Injection 200 mg in 1.14 mL single dose pre-filled pen

Injection

Dupixent

13

Dupilumab

Injection 300 mg in 2 mL single dose pre-filled syringe

Injection

Dupixent

14

Dupilumab

Injection 300 mg in 2 mL single dose pre-filled pen

Injection

Dupixent

15

Eletriptan

Tablet 40 mg (as hydrobromide)

Oral

Relpax

16

Eletriptan

Tablet 80 mg (as hydrobromide)

Oral

Relpax

17

Febuxostat

Tablet 80 mg

Oral

Adenuric

18

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 20 mg

Oral

Vyvanse

19

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 30 mg

Oral

Vyvanse

20

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 40 mg

Oral

Vyvanse

21

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 50 mg

Oral

Vyvanse

22

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 60 mg

Oral

Vyvanse

23

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 70 mg

Oral

Vyvanse

24

Lutropin alfa

Powder for injection 75 I.U. with solvent

Injection

Luveris

25

Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A

Oral liquid 125 mL, 24 (Renastep)

Oral

Renastep

26

Romiplostim

 

Powder for injection 375

micrograms

Injection

 

Nplate

27

Romiplostim

 

Powder for injection 625

micrograms

Injection

Nplate

28

Romosozumab

Injection 105 mg in 1.17 mL single use pre-filled syringe

Injection

Evenity

29

Semaglutide

Solution for injection 2 mg in 1.5 mL pre-filled pen

Injection

Ozempic

30

Semaglutide

Solution for injection 2 mg in 3 mL pre-filled pen

Injection

Ozempic

31

Semaglutide

Solution for injection 4 mg in 3 mL pre-filled pen

Injection

Ozempic

32

Stiripentol

Capsule 250 mg

Oral

Diacomit

33

Stiripentol

Capsule 500 mg

Oral

Diacomit

34

Stiripentol

Powder for oral suspension 250 mg

Oral

Diacomit

35

Stiripentol

Powder for oral suspension 500 mg

Oral

Diacomit

36

Trametinib

Powder for oral solution 50 micrograms per mL (as dimethylsulfoxide), 90 mL

Oral

Mekinist

Schedule 2 Brands of pharmaceutical items with approved ex-manufacturer price reduced by a lower percentage than would otherwise apply

 

Column 1

Column 2

Column 3

Item

Brand of pharmaceutical item

% reduction

 

Drug

Form

Manner of administration

Brand

 

1

Golimumab

Injection 50 mg in 0.5 mL single use pre-filled syringe

Injection

Simponi

10%

2

Golimumab

Injection 50 mg in 0.5 mL single use pre-filled pen

Injection

Simponi

10%

3

Golimumab

Injection 100 mg in 1 mL single use pre-filled pen

Injection

Simponi

10%